Weight loss drug candidates multiply, spurring hopes of better outcomes, lower costs
(This June 27 story has been corrected to say that Versanis drug was licensed from Novartis in paragraph 19) By Deena Beasley SAN DIEGO (Reuters) – New data on weight loss drugs that could compete with Novo Nordisk’s Wegovy are raising expectations there will soon be more options, and possibly lower prices, in an estimated…
